Krystal Biotech (NASDAQ:KRYS - Get Free Report) announced its quarterly earnings data on Monday. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23, Zacks reports. The firm had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company's quarterly revenue was up 116.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.30 EPS.
Krystal Biotech Price Performance
Shares of Krystal Biotech stock traded up $5.24 during trading on Friday, hitting $187.86. 293,571 shares of the company were exchanged, compared to its average volume of 257,757. The firm has a market capitalization of $5.40 billion, a P/E ratio of 62.83 and a beta of 0.84. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34. The firm's fifty day moving average price is $157.37 and its 200 day moving average price is $175.23.
Insider Transactions at Krystal Biotech
In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 14.10% of the company's stock.
Analysts Set New Price Targets
Several brokerages have weighed in on KRYS. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday. Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday. Citigroup boosted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday. Finally, HC Wainwright reissued a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $210.00.
Check Out Our Latest Stock Report on KRYS
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
See Also
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
